2023-505862-27-00CompletedPhase 1
A clinical trial to learn how an investigational drug (norucholic acid) is absorbed, distributed, broken down, and removed from the body when given to people with kidney problems
Source: EU CTIS (euclinicaltrials.eu) · Last updated 13 May 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 5 Jul 2023
- Start date
- 10 Oct 2023
- Lead sponsor
- Dr. Falk Pharma GmbH
- Diseases
- Fatty liver disease (MASLD/MASH)
- EU CT number
- 2023-505862-27-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 48
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CRU Hungary Kft. | Kistarcsa | Hungary | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.